미국의 중재적 종양학 시술 시장 규모, 점유율, 동향 분석 보고서 : 방법별, 시술별, 암 유형별, 최종 용도별 및 부문별 예측(2026-2033년)

U.S. Interventional Oncology Procedures Market Summary

The U.S. interventional oncology procedures market size was valued at USD 10.8 billion in 2025 and is projected to grow from USD 12.0 billion in 2026 to USD 23.4 billion by 2033, at a CAGR of 9.9% from 2026 to 2033. This growth can be attributed to the increasing prevalence of cancer, rising technological advancements in minimally invasive procedures, growing geriatric population, increasing focus on early cancer detection, and growing public and private investments in the field of interventional oncology.

There is a significant rise in the number of cancer cases globally, which drives the need for advanced solutions to facilitate better cancer care. The growing advancements of minimally invasive techniques in interventional oncology are reshaping cancer treatment by enabling more precise and targeted therapies. Advanced ablation systems are playing a crucial role in this shift, as they allow for more effective tumor destruction with minimal impact on surrounding tissues. The ability to deliver controlled, repeatable thermal energy to tumors, particularly in bone and soft tissues, has enhanced the reliability of interventional oncology procedures. For instance, in September 2022, Stryker's OptaBlate bone tumor ablation system received FDA clearance. This interventional oncology technology features patented micro-infusion technology, enabling quicker, more consistent ablations and the simultaneous treatment of two vertebral body levels. OptaBlate offers a reliable solution for patients with painful metastatic tumors. These technological improvements reduce patient recovery time and offer an alternative to systemic treatments, which often have significant side effects. As a result, interventional oncology is becoming an increasingly preferred option for patients with metastatic cancers, improving both pain management and overall outcomes.

The adoption of microwave ablation, cryoablation, irreversible electroporation (IRE), and radioembolization has expanded significantly in recent years due to their ability to treat tumors with shorter hospital stays and fewer complications than conventional surgery. In particular, microwave ablation systems are gaining preference because they provide faster heating, larger ablation zones, and improved efficacy in highly vascular tumors. In July 2024, IceCure Medical announced that the U.S. FDA granted regulatory clearance for its next-generation XSense cryoablation system with CryoProbes. The minimally invasive technology is intended to destroy tumors through controlled freezing and offers an alternative to surgical tumor removal, highlighting continued advancements in cryoablation technologies within interventional oncology. These advancements are helping clinicians perform outpatient or same-day procedures, thereby improving patient convenience and reducing healthcare costs.

Moreover, the growing geriatric population is further driving the growth of the U.S. interventional oncology procedures industry, primarily due to the higher incidence of cancer among older adults. As age increases, prolonged exposure to carcinogens, the accumulation of genetic mutations, and declining immune function significantly elevate the risk of cancer development, leading to greater demand for minimally invasive cancer treatments. For instance, the U.S. population aged 65 years and older reached approximately 59.8 million in 2023, expanding the pool of patients eligible for interventional oncology procedures. Similarly, in March 2024, the U.S. Centers for Disease Control and Prevention (CDC) emphasized the importance of routine cancer screening programs through its national awareness initiatives focused on breast, colorectal, cervical, and lung cancers. The organization highlighted that regular screening and early diagnosis improve treatment effectiveness and survival outcomes, further supporting the growing clinical adoption of targeted and minimally invasive oncology therapies. Increasing public awareness regarding cancer symptoms and preventive healthcare is therefore expected to contribute to higher procedural volumes in the interventional oncology market over the forecast period.

Increasing public and private investments in interventional oncology will further accelerating the market growth by expanding research, innovation, and infrastructure. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping to guide precision interventions for HCC.

U.S. Interventional Oncology Procedures Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the U.S. interventional oncology procedures market report based on technique, procedure, cancer type, and end-use:

• Technique Outlook (Revenue, USD Billion, 2021 - 2033)
• Ablation Therapies
• Embolization Therapies
• Biopsy Techniques
• Targeted Therapy Delivery Systems
• Image-Guided Procedures
• Procedures Outlook (Revenue, USD Billion, 2021 - 2033)
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care
• Cancer Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Liver Cancer
• Lung Cancer
• Kidney
• Prostate cancer
• Others
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Ambulatory Surgical Centers
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technique
  • 1.2.2. Procedure
  • 1.2.3. Cancer Type
  • 1.2.4. End Use
  • 1.2.5. Country scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technique outlook
  • 2.2.2. Procedure outlook
  • 2.2.3. Cancer Type outlook
  • 2.2.4. End Use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Interventional Oncology Procedures Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Interventional Oncology Procedures Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. U.S. Interventional Oncology Procedures Market: Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Interventional Oncology Procedures Market: Technique Movement Analysis
• 4.3. U.S. Interventional Oncology Procedures Market by Technique Outlook (USD Billion)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Ablation Therapies
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.6. Embolization Therapies
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.7. Biopsy Techniques
  • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.8. Targeted Therapy Delivery Systems
  • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.9. Image-Guided Procedures
  • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Interventional Oncology Procedures Market: Procedure Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Interventional Oncology Procedures Market: Procedure Movement Analysis
• 5.3. U.S. Interventional Oncology Procedures Market by Procedure Outlook (USD Billion)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Tumor Ablation
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Tumor Biopsy
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Vascular Interventions
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.8. Palliative Care
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Interventional Oncology Procedures Market: Cancer Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Interventional Oncology Procedures Market: Cancer Type Movement Analysis
• 6.3. U.S. Interventional Oncology Procedures Market by Cancer Type Outlook (USD Billion)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Liver Cancer
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Lung Cancer
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.7. Kidney
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.8. Prostate cancer
  • 6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.9. Others
  • 6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Interventional Oncology Procedures Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Interventional Oncology Procedures Market: End-Use Movement Analysis
• 7.3. U.S. Interventional Oncology Procedures Market by End Use Outlook (USD Billion)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Hospitals
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Ambulatory Surgical Centers
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Others
  • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Medtronic
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product/Service Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Boston Scientific Corporation
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product/Service Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Johnson & Johnson MedTech
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product/Service Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Cook Medical
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product/Service Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. AngioDynamics Inc.
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product/Service Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Stryker Corporation
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product/Service Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Terumo Corporation
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product/Service Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Siemens Healthineers AG
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product/Service Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Baxter International Inc.
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product/Service Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Becton, Dickinson and Company
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product/Service Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. B. Braun
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Product/Service Benchmarking
    • 8.2.11.4. Strategic Initiatives
  • 8.2.12. GE Healthcare
    • 8.2.12.1. Company Overview
    • 8.2.12.2. Financial Performance
    • 8.2.12.3. Product/Service Benchmarking
    • 8.2.12.4. Strategic Initiatives